ROIV – Roivant Sciences Ltd

ROIV — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

5.44

Margin Of Safety %

Put/Call OI Ratio

0.59

EPS Next Q Diff

0.03

EPS Last/This Y

-0.73

EPS This/Next Y

-0.19

Price

29.28

Target Price

35.71

Analyst Recom

1.29

Performance Q

10.74

Upside

-151.9%

Beta

1.13

Ticker: ROIV

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-16	ROIV	29.19	0.75	0.03	34431
2026-04-17	ROIV	29.8	0.74	8.79	34538
2026-04-20	ROIV	29.08	0.81	4.51	33570
2026-04-21	ROIV	29.28	0.83	2.88	33977
2026-04-22	ROIV	29.15	0.85	0.27	34730
2026-04-23	ROIV	28.13	0.85	2.58	34735
2026-04-24	ROIV	27.39	0.88	0.36	35008
2026-04-27	ROIV	27.84	0.88	0.25	35038
2026-04-28	ROIV	27.77	0.88	1.50	35044
2026-04-29	ROIV	27.51	0.88	0.94	35056
2026-04-30	ROIV	28.53	0.88	0.07	35101
2026-05-01	ROIV	27.84	0.88	1.00	35149
2026-05-04	ROIV	28.36	0.88	1.19	35150
2026-05-05	ROIV	28.32	0.88	0.23	35175
2026-05-06	ROIV	28.81	0.88	1.95	35301
2026-05-07	ROIV	28.28	0.88	0.63	35528
2026-05-08	ROIV	28.57	0.88	0.03	35558
2026-05-11	ROIV	28.95	1.20	0.01	30548
2026-05-12	ROIV	29.4	1.20	0.07	30547
2026-05-13	ROIV	29.23	0.58	0.33	45394
2026-05-14	ROIV	29.5	0.58	0.49	45408
2026-05-15	ROIV	29.27	0.59	0.30	45706
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-16	ROIV	29.21	-60.2	-	-0.97
2026-04-17	ROIV	29.81	-60.2	-	-0.97
2026-04-20	ROIV	29.09	-60.2	-	-0.97
2026-04-21	ROIV	29.28	-60.2	-	-0.97
2026-04-22	ROIV	29.15	-60.2	-	-0.97
2026-04-23	ROIV	28.13	-60.2	-	-0.97
2026-04-24	ROIV	27.40	-60.2	-	-0.97
2026-04-27	ROIV	27.85	-60.2	-	-0.97
2026-04-28	ROIV	27.77	-60.2	-	-0.97
2026-04-29	ROIV	27.51	-60.2	-	-0.97
2026-04-30	ROIV	28.53	-60.2	-	-0.97
2026-05-01	ROIV	27.83	-60.2	-	-0.97
2026-05-04	ROIV	28.35	-60.2	-	-0.97
2026-05-05	ROIV	28.32	-60.2	-	-0.97
2026-05-06	ROIV	28.81	-60.2	-	-0.97
2026-05-07	ROIV	28.29	-60.2	-	-0.97
2026-05-08	ROIV	28.56	-60.2	-	-0.97
2026-05-11	ROIV	28.96	-60.2	-	-0.97
2026-05-12	ROIV	29.40	-60.2	-	-0.97
2026-05-13	ROIV	29.23	-60.2	-	-0.97
2026-05-14	ROIV	29.50	-60.2	-	-0.97
2026-05-15	ROIV	29.28	-60.2	-	-0.97
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-17	ROIV	-10.52	2.15	5.10
2026-04-20	ROIV	-10.22	2.11	5.10
2026-04-21	ROIV	-10.32	2.11	5.10
2026-04-22	ROIV	-10.32	2.11	5.10
2026-04-23	ROIV	-10.39	2.11	5.10
2026-04-24	ROIV	-10.39	2.11	5.10
2026-04-27	ROIV	-10.39	0.45	5.00
2026-04-28	ROIV	-10.42	0.45	5.00
2026-04-29	ROIV	-10.42	0.45	5.00
2026-04-30	ROIV	-10.42	0.45	5.00
2026-05-01	ROIV	-10.42	0.45	5.00
2026-05-04	ROIV	-10.42	-1.36	5.00
2026-05-05	ROIV	-10.42	-1.36	5.00
2026-05-06	ROIV	-10.42	-1.36	5.00
2026-05-07	ROIV	-10.42	-1.36	5.00
2026-05-08	ROIV	-10.35	-1.36	5.00
2026-05-11	ROIV	-10.35	-1.97	4.92
2026-05-12	ROIV	-10.70	-1.97	5.44
2026-05-13	ROIV	-10.70	-1.97	5.44
2026-05-14	ROIV	-10.70	-1.97	5.44
2026-05-15	ROIV	-10.70	-1.97	5.44
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.36

Avg. EPS Est. Current Quarter

-0.31

Avg. EPS Est. Next Quarter

-0.33

Insider Transactions

-10.7

Institutional Transactions

-1.97

Beta

1.13

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

3.5

Max Drawdown 5-Year %

Target Price

35.71

P/E

Forward P/E

PEG

P/S

1574.97

P/B

4.87

P/Free Cash Flow

EPS

-1.17

Average EPS Est. Cur. Y

-0.97

EPS Next Y. (Est.)

-1.16

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-6079.94

Relative Volume

1.34

Return on Equity vs Sector %

-45.9

Return on Equity vs Industry %

-30.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.12

EBIT Estimation

◆ ROIV Healthcare

$29.29

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

0/20

Pullback

10/25

Volume

3/15

Valuation

6/20

TP/AR

4/10

Options

5/10

RSI

56.7

Range 1M

72%

Sup Dist

0.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

4/30

Estimates

3/20

Inst/Vol

5/15

Options

8/10

EPS Yr

-367.2%

EPS NY

-5.5%

52W%

94.8%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +21.9% upside

Quality

7/30

Valuation

6/30

Growth

1/25

Stability

6/10

LT Trend

1/5

Upside

+21.9%

Quality

Roivant Sciences Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 750

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

ROIV

Latest News

—

Caricamento notizie per ROIV…

stock quote shares ROIV – Roivant Sciences Ltd Stock Price stock today

news today ROIV – Roivant Sciences Ltd stock forecast ,stock prediction 2023 2024 2025

marketwatch ROIV – Roivant Sciences Ltd yahoo finance google finance

stock history ROIV – Roivant Sciences Ltd invest stock market

stock prices ROIV premarket after hours

ticker ROIV fair value insiders trading

RNAM – Avidity Biosciences Inc

RNAM — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

6.18

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

72.82

Target Price

Analyst Recom

Performance Q

2.13

Upside

N/A

Beta

0.98

Ticker: RNAM

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-16	RNAM	72.82	N/A	N/A	0
2026-04-17	RNAM	72.82	N/A	N/A	0
2026-04-20	RNAM	72.82	N/A	N/A	0
2026-04-21	RNAM	72.82	N/A	N/A	0
2026-04-22	RNAM	72.82	N/A	N/A	0
2026-04-23	RNAM	72.82	N/A	N/A	0
2026-04-24	RNAM	72.82	N/A	N/A	0
2026-04-27	RNAM	72.82	N/A	N/A	0
2026-04-28	RNAM	72.82	N/A	N/A	0
2026-04-29	RNAM	72.82	N/A	N/A	0
2026-04-30	RNAM	72.82	N/A	N/A	0
2026-05-01	RNAM	72.82	N/A	N/A	0
2026-05-04	RNAM	72.82	N/A	N/A	0
2026-05-05	RNAM	72.82	N/A	N/A	0
2026-05-06	RNAM	72.82	N/A	N/A	0
2026-05-07	RNAM	72.82	N/A	N/A	0
2026-05-08	RNAM	72.82	N/A	N/A	0
2026-05-11	RNAM	72.82	N/A	N/A	0
2026-05-12	RNAM	72.82	N/A	N/A	0
2026-05-13	RNAM	72.82	N/A	N/A	0
2026-05-14	RNAM	72.82	N/A	N/A	0
2026-05-15	RNAM	72.82	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

0.98

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

602.56

P/B

6.52

P/Free Cash Flow

EPS

-4.96

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3650.39

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

No data found for RNAM

RNAM

Latest News

—

Caricamento notizie per RNAM…

stock quote shares RNAM – Avidity Biosciences Inc Stock Price stock today

news today RNAM – Avidity Biosciences Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch RNAM – Avidity Biosciences Inc yahoo finance google finance

stock history RNAM – Avidity Biosciences Inc invest stock market

stock prices RNAM premarket after hours

ticker RNAM fair value insiders trading

RGC – Regencell Bioscience Holdings Ltd

RGC — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.38

Margin Of Safety %

Put/Call OI Ratio

0.84

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

28.5

Target Price

Analyst Recom

Performance Q

-8.46

Upside

-100.5%

Beta

1.73

Ticker: RGC

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-16	RGC	30.45	1.08	0.26	6543
2026-04-17	RGC	28.57	1.10	0.60	6606
2026-04-20	RGC	28	1.74	0.31	3453
2026-04-21	RGC	28.15	1.80	0.12	3433
2026-04-22	RGC	29.27	1.35	0.37	3930
2026-04-23	RGC	28.49	1.15	0.27	4707
2026-04-24	RGC	27.41	1.25	0.45	4635
2026-04-27	RGC	29.12	1.03	0.09	5292
2026-04-28	RGC	28.86	1.02	0.53	5359
2026-04-29	RGC	28.89	0.99	0.92	5456
2026-04-30	RGC	29.36	1.09	0.03	5557
2026-05-01	RGC	29.07	1.05	0.13	5655
2026-05-04	RGC	27.25	1.05	0.04	5693
2026-05-05	RGC	27.2	1.13	0.65	5515
2026-05-06	RGC	27.56	1.13	1.73	5548
2026-05-07	RGC	31.76	1.23	0.16	5657
2026-05-08	RGC	29.5	1.04	0.03	6162
2026-05-11	RGC	27.35	0.91	0.19	6604
2026-05-12	RGC	27.03	0.83	0.58	7119
2026-05-13	RGC	27.42	0.88	0.05	7064
2026-05-14	RGC	27.165	0.83	0.18	7278
2026-05-15	RGC	28.5	0.84	0.17	7334
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-16	RGC	30.43	-	-	-
2026-04-17	RGC	28.77	-	-	-
2026-04-20	RGC	28.10	-	-	-
2026-04-21	RGC	28.17	-	-	-
2026-04-22	RGC	29.38	-	-	-
2026-04-23	RGC	28.36	-	-	-
2026-04-24	RGC	27.42	-	-	-
2026-04-27	RGC	29.23	-	-	-
2026-04-28	RGC	29.00	-	-	-
2026-04-29	RGC	29.00	-	-	-
2026-04-30	RGC	29.47	-	-	-
2026-05-01	RGC	29.09	-	-	-
2026-05-04	RGC	27.30	-	-	-
2026-05-05	RGC	27.27	-	-	-
2026-05-06	RGC	27.57	-	-	-
2026-05-07	RGC	31.87	-	-	-
2026-05-08	RGC	29.30	-	-	-
2026-05-11	RGC	27.35	-	-	-
2026-05-12	RGC	27.28	-	-	-
2026-05-13	RGC	27.24	-	-	-
2026-05-14	RGC	27.04	-	-	-
2026-05-15	RGC	28.50	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-17	RGC	0.00	-7.58	1.24
2026-04-20	RGC	0.00	-7.49	1.24
2026-04-21	RGC	0.00	-7.49	1.24
2026-04-22	RGC	0.00	-7.49	1.25
2026-04-23	RGC	0.00	-7.49	1.25
2026-04-24	RGC	0.00	-7.49	1.25
2026-04-27	RGC	0.00	-7.46	1.48
2026-04-28	RGC	0.00	-7.46	1.48
2026-04-29	RGC	0.00	-7.46	1.48
2026-04-30	RGC	0.00	-7.46	1.48
2026-05-01	RGC	0.00	-7.46	1.48
2026-05-04	RGC	0.00	-7.46	1.48
2026-05-05	RGC	0.00	-7.46	1.48
2026-05-06	RGC	0.00	-7.46	1.48
2026-05-07	RGC	0.00	-7.46	1.48
2026-05-08	RGC	0.00	-7.46	1.48
2026-05-11	RGC	0.00	-7.46	1.48
2026-05-12	RGC	0.00	-7.46	1.38
2026-05-13	RGC	0.00	-7.46	1.38
2026-05-14	RGC	0.00	-7.46	1.38
2026-05-15	RGC	0.00	-7.46	1.38
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-7.46

Beta

1.73

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

11570.85

P/Free Cash Flow

EPS

-0.01

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.88

Return on Equity vs Sector %

-605

Return on Equity vs Industry %

-586.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ RGC Healthcare

$28.58

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

9/25

Volume

7/15

Valuation

6/20

TP/AR

2/10

Options

5/10

RSI

51.3

Range 1M

50.9%

Sup Dist

8.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

7/30

Estimates

0/20

Inst/Vol

1/15

Options

5/10

EPS Yr

EPS NY

52W%

27.6%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

Quality

2/30

Valuation

2/30

Growth

3/25

Stability

4/10

LT Trend

4/5

Quality

Regencell Bioscience Holdings L

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 10

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

RGC

Latest News

—

Caricamento notizie per RGC…

stock quote shares RGC – Regencell Bioscience Holdings Ltd Stock Price stock today

news today RGC – Regencell Bioscience Holdings Ltd stock forecast ,stock prediction 2023 2024 2025

marketwatch RGC – Regencell Bioscience Holdings Ltd yahoo finance google finance

stock history RGC – Regencell Bioscience Holdings Ltd invest stock market

stock prices RGC premarket after hours

ticker RGC fair value insiders trading

ONC – BeOne Medicines Ltd ADR

ONC — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.09

Margin Of Safety %

-1

Put/Call OI Ratio

1.09

EPS Next Q Diff

-0.29

EPS Last/This Y

-1.94

EPS This/Next Y

2.92

Price

294.06

Target Price

413.26

Analyst Recom

1.23

Performance Q

-15.26

Upside

-46.5%

Beta

0.51

Ticker: ONC

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-16	ONC	320.82	1.43	4.05	3406
2026-04-17	ONC	323.32	1.42	1.77	3429
2026-04-20	ONC	318.26	1.37	0.46	3036
2026-04-21	ONC	312.27	1.37	10.00	3047
2026-04-22	ONC	312.26	1.37	1.24	3057
2026-04-23	ONC	299.55	1.35	10.35	3382
2026-04-24	ONC	300.76	1.46	0.50	3604
2026-04-27	ONC	298.92	1.46	0.25	3605
2026-04-28	ONC	297.92	1.45	1.25	3611
2026-04-29	ONC	290.61	1.44	0.33	3614
2026-04-30	ONC	295.31	1.24	0.00	3340
2026-05-01	ONC	293.43	1.23	999.99	2877
2026-05-04	ONC	297.15	1.23	0.60	2878
2026-05-05	ONC	297.38	1.23	0.02	2880
2026-05-06	ONC	313.24	1.24	0.31	2865
2026-05-07	ONC	317.24	1.23	0.27	2883
2026-05-08	ONC	311.96	1.23	0.62	2883
2026-05-11	ONC	310.58	1.18	0.05	2866
2026-05-12	ONC	314.82	1.15	1.60	2820
2026-05-13	ONC	316.07	1.15	0.33	2846
2026-05-14	ONC	304.48	1.11	0.56	2845
2026-05-15	ONC	293.09	1.09	3.53	2815
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-16	ONC	321.25	8351.1	345.5	5.52
2026-04-17	ONC	324.46	8351.1	304.3	5.52
2026-04-20	ONC	318.68	8351.1	304.8	5.52
2026-04-21	ONC	314.67	8351.1	304.0	5.52
2026-04-22	ONC	312.00	8351.1	304.6	5.52
2026-04-23	ONC	299.89	8351.1	282.6	5.52
2026-04-24	ONC	300.53	8351.1	299.1	5.61
2026-04-27	ONC	299.77	8595.0	307.3	5.73
2026-04-28	ONC	298.57	8595.0	307.5	5.73
2026-04-29	ONC	290.90	8595.0	295.5	5.73
2026-04-30	ONC	296.88	7957.5	310.5	5.67
2026-05-01	ONC	294.02	7957.5	327.4	5.67
2026-05-04	ONC	297.19	7957.5	337.0	5.67
2026-05-05	ONC	296.65	7957.5	321.1	5.67
2026-05-06	ONC	311.78	7957.5	367.8	5.67
2026-05-07	ONC	316.66	7957.5	408.6	5.67
2026-05-08	ONC	312.76	53.7	40.4	5.67
2026-05-11	ONC	310.28	53.7	68.8	5.67
2026-05-12	ONC	314.61	84.4	74.7	6.12
2026-05-13	ONC	315.96	84.4	78.4	6.12
2026-05-14	ONC	305.47	84.4	69.3	6.12
2026-05-15	ONC	294.06	84.4	53.4	6.12
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-17	ONC	-19.97	0.90	1.20
2026-04-20	ONC	-19.97	1.00	1.20
2026-04-21	ONC	-19.97	1.00	1.20
2026-04-22	ONC	-19.97	1.00	1.20
2026-04-23	ONC	-18.77	1.00	1.20
2026-04-24	ONC	-18.77	1.00	1.20
2026-04-27	ONC	-18.77	0.91	1.14
2026-04-28	ONC	-18.77	0.91	1.14
2026-04-29	ONC	-18.77	0.91	1.14
2026-04-30	ONC	-18.77	0.91	1.14
2026-05-01	ONC	-18.77	0.91	1.14
2026-05-04	ONC	-18.77	1.06	1.14
2026-05-05	ONC	-18.77	1.06	1.14
2026-05-06	ONC	-18.77	1.06	1.14
2026-05-07	ONC	-18.77	1.06	1.14
2026-05-08	ONC	-18.77	1.06	1.13
2026-05-11	ONC	-18.73	1.17	1.13
2026-05-12	ONC	-18.73	1.17	1.09
2026-05-13	ONC	-18.73	1.17	1.09
2026-05-14	ONC	-18.73	1.17	1.09
2026-05-15	ONC	-16.64	1.17	1.09
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

1.96

Avg. EPS Est. Current Quarter

1.55

Avg. EPS Est. Next Quarter

1.67

Insider Transactions

-16.64

Institutional Transactions

1.17

Beta

0.51

Average Sales Estimate Current Quarter

1595

Average Sales Estimate Next Quarter

1665

Fair Value

291.19

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

31.1

Max Drawdown 5-Year %

-70

Target Price

413.26

P/E

65.44

Forward P/E

30.44

PEG

0.43

P/S

5.21

P/B

6.85

P/Free Cash Flow

26.85

EPS

4.48

Average EPS Est. Cur. Y

6.12

EPS Next Y. (Est.)

9.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

8.94

Relative Volume

1.12

Return on Equity vs Sector %

-16.2

Return on Equity vs Industry %

-0.6

EPS 1 7Days Diff

0.4

EPS 1 30Days Diff

0.62

EBIT Estimation

53.4

◆ ONC Healthcare

$293.27

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

12/25

Volume

4/15

Valuation

15/20

TP/AR

2/10

Options

2/10

RSI

41.1

Range 1M

14.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

29/30

Estimates

5/20

Inst/Vol

6/15

Options

3/10

EPS Yr

148.1%

EPS NY

47.7%

52W%

43.1%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +11.9% upside

Quality

14/30

Valuation

7/30

Growth

21/25

Stability

6/10

LT Trend

3/5

Upside

+11.9%

Quality

MoS

-1%

BeOne Medicines Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 12000

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

ONC

Latest News

—

Caricamento notizie per ONC…

stock quote shares ONC – BeOne Medicines Ltd ADR Stock Price stock today

news today ONC – BeOne Medicines Ltd ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch ONC – BeOne Medicines Ltd ADR yahoo finance google finance

stock history ONC – BeOne Medicines Ltd ADR invest stock market

stock prices ONC premarket after hours

ticker ONC fair value insiders trading

MDLN – Medline Inc

MDLN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

3.93

Margin Of Safety %

Put/Call OI Ratio

0.51

EPS Next Q Diff

0.05

EPS Last/This Y

0.08

EPS This/Next Y

0.15

Price

36.16

Target Price

51.56

Analyst Recom

1.55

Performance Q

-18.77

Upside

-27.1%

Beta

Ticker: MDLN

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-16	MDLN	46.95	0.22	2.87	38721
2026-04-17	MDLN	47.63	0.28	0.86	40446
2026-04-20	MDLN	48.26	0.48	0.12	17985
2026-04-21	MDLN	47.5	0.43	1.23	20022
2026-04-22	MDLN	47.15	0.44	2.04	20334
2026-04-23	MDLN	46.21	0.44	2.89	20364
2026-04-24	MDLN	44.77	0.45	1.33	20621
2026-04-27	MDLN	45.22	0.46	0.79	18778
2026-04-28	MDLN	44.24	0.51	0.43	17828
2026-04-29	MDLN	43.39	0.51	0.53	17978
2026-04-30	MDLN	44.46	0.53	3.59	18006
2026-05-01	MDLN	44.75	0.53	0.03	18014
2026-05-04	MDLN	44.19	0.48	7.27	19196
2026-05-05	MDLN	45.34	0.64	11.08	21536
2026-05-06	MDLN	42.01	0.57	0.74	20906
2026-05-07	MDLN	42	0.55	1.49	23208
2026-05-08	MDLN	39.53	0.54	1.05	23175
2026-05-11	MDLN	39.26	0.54	0.52	24341
2026-05-12	MDLN	38.56	0.55	1.60	25546
2026-05-13	MDLN	38.74	0.53	0.32	25325
2026-05-14	MDLN	38.91	0.51	0.11	25323
2026-05-15	MDLN	36.18	0.51	1.50	25417
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-16	MDLN	46.94	-	503.8	1.47
2026-04-17	MDLN	47.66	-	577.2	1.47
2026-04-20	MDLN	48.28	-	573.2	1.47
2026-04-21	MDLN	47.52	-	514.6	1.47
2026-04-22	MDLN	47.15	-	531.0	1.47
2026-04-23	MDLN	46.22	-	505.2	1.47
2026-04-24	MDLN	44.75	-	480.5	1.47
2026-04-27	MDLN	45.22	-	566.4	1.47
2026-04-28	MDLN	44.24	-	501.4	1.47
2026-04-29	MDLN	43.38	-	506.6	1.47
2026-04-30	MDLN	44.47	-	596.7	1.47
2026-05-01	MDLN	44.76	-	559.4	1.47
2026-05-04	MDLN	44.22	-	521.9	1.47
2026-05-05	MDLN	45.34	-	598.7	1.47
2026-05-06	MDLN	42.00	-	396.7	1.47
2026-05-07	MDLN	41.99	-	433.3	1.47
2026-05-08	MDLN	39.53	-	560.6	1.47
2026-05-11	MDLN	39.25	-	656.7	1.50
2026-05-12	MDLN	38.53	-	634.6	1.51
2026-05-13	MDLN	38.71	-	679.2	1.51
2026-05-14	MDLN	38.90	-	680.4	1.51
2026-05-15	MDLN	36.16	-	501.5	1.51
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-17	MDLN	-30.40	24.97	4.88
2026-04-20	MDLN	-30.40	25.09	4.88
2026-04-21	MDLN	-30.40	25.09	4.88
2026-04-22	MDLN	-30.40	25.09	4.69
2026-04-23	MDLN	-31.46	25.09	4.69
2026-04-24	MDLN	-31.46	25.09	4.69
2026-04-27	MDLN	-31.46	25.19	3.99
2026-04-28	MDLN	-31.46	25.19	3.99
2026-04-29	MDLN	-31.46	25.19	3.99
2026-04-30	MDLN	-31.46	25.19	3.99
2026-05-01	MDLN	-31.46	25.19	4.00
2026-05-04	MDLN	-31.45	25.57	3.99
2026-05-05	MDLN	-31.46	25.57	3.99
2026-05-06	MDLN	-31.46	25.57	3.99
2026-05-07	MDLN	-31.46	25.57	3.99
2026-05-08	MDLN	-31.46	25.57	3.99
2026-05-11	MDLN	-32.02	25.88	3.99
2026-05-12	MDLN	-32.02	25.88	3.93
2026-05-13	MDLN	-32.02	25.88	3.93
2026-05-14	MDLN	-32.02	25.88	3.93
2026-05-15	MDLN	-32.02	25.88	3.93
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.33

Avg. EPS Est. Current Quarter

0.32

Avg. EPS Est. Next Quarter

0.38

Insider Transactions

-32.02

Institutional Transactions

25.88

Beta

Average Sales Estimate Current Quarter

7523

Average Sales Estimate Next Quarter

7724

Fair Value

56.25

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

28.9

Max Drawdown 5-Year %

Target Price

51.56

P/E

30.27

Forward P/E

21.93

PEG

2.34

P/S

1.63

P/B

2.72

P/Free Cash Flow

45.49

EPS

1.2

Average EPS Est. Cur. Y

1.51

EPS Next Y. (Est.)

1.66

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.32

Relative Volume

1.1

Return on Equity vs Sector %

-18.3

Return on Equity vs Industry %

-1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

501.5

◆ MDLN Healthcare

$36.19

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

18/20

Pullback

5/25

Volume

1/15

Valuation

16/20

TP/AR

1/10

Options

6/10

RSI

25.3

Range 1M

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

18/25

Growth

11/30

Estimates

2/20

Inst/Vol

7/15

Options

4/10

EPS Yr

5.4%

EPS NY

9.5%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +25.6% upside

Quality

3/30

Valuation

15/30

Growth

7/25

Stability

5/10

LT Trend

1/5

Upside

+25.6%

Quality

MoS

56%

Medline Inc.

Sector: Healthcare

Industry: Medical Instruments & Supplies

Employees: 45000

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services, such as consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. The company was founded in 1966 and is based in Northfield, Illinois.

MDLN

Latest News

—

Caricamento notizie per MDLN…

stock quote shares MDLN – Medline Inc Stock Price stock today

news today MDLN – Medline Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch MDLN – Medline Inc yahoo finance google finance

stock history MDLN – Medline Inc invest stock market

stock prices MDLN premarket after hours

ticker MDLN fair value insiders trading

COGT – Cogent Biosciences Inc

COGT — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

8.14

Margin Of Safety %

Put/Call OI Ratio

0.57

EPS Next Q Diff

-0.02

EPS Last/This Y

-0.05

EPS This/Next Y

1.26

Price

32.69

Target Price

54.25

Analyst Recom

1.31

Performance Q

-10.54

Upside

-369.9%

Beta

0.34

Ticker: COGT

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-16	COGT	36.18	0.97	2.89	28106
2026-04-17	COGT	37.25	0.93	0.03	28884
2026-04-20	COGT	36.97	0.78	1.60	23063
2026-04-21	COGT	36.73	0.80	2.75	23523
2026-04-22	COGT	36.4	0.81	1.67	23808
2026-04-23	COGT	36.12	0.82	0.49	23992
2026-04-24	COGT	36.81	0.81	0.06	24617
2026-04-27	COGT	36.6	0.80	0.13	24754
2026-04-28	COGT	36.36	0.71	1.35	27392
2026-04-29	COGT	35.88	0.71	3.46	27499
2026-04-30	COGT	35.76	0.71	0.18	27666
2026-05-01	COGT	36.65	0.71	2.04	27728
2026-05-04	COGT	36.7	0.72	1.92	27840
2026-05-05	COGT	37	0.69	2.24	28606
2026-05-06	COGT	35.88	0.69	3.09	28715
2026-05-07	COGT	34.79	0.71	2.34	29140
2026-05-08	COGT	34.76	0.72	0.05	29457
2026-05-11	COGT	34.12	0.70	1.24	30007
2026-05-12	COGT	34.54	0.70	0.50	30382
2026-05-13	COGT	34.3	0.68	0.41	31350
2026-05-14	COGT	34.2	0.67	0.58	31649
2026-05-15	COGT	32.68	0.57	3.20	29885
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-16	COGT	36.18	-3.9	-	-2.15
2026-04-17	COGT	37.24	-3.9	-	-2.15
2026-04-20	COGT	37.01	-3.9	-	-2.15
2026-04-21	COGT	36.71	-3.9	-	-2.15
2026-04-22	COGT	36.39	-3.9	-	-2.15
2026-04-23	COGT	36.14	-3.9	-	-2.15
2026-04-24	COGT	36.86	-3.9	-	-2.15
2026-04-27	COGT	36.60	-3.9	-	-2.15
2026-04-28	COGT	36.37	-3.9	-	-2.15
2026-04-29	COGT	35.88	-3.9	-	-2.15
2026-04-30	COGT	35.79	-3.9	-	-2.15
2026-05-01	COGT	36.63	-3.9	-	-2.15
2026-05-04	COGT	36.73	-3.9	-	-2.15
2026-05-05	COGT	36.99	-3.9	-	-2.15
2026-05-06	COGT	35.85	-3.9	-	-2.15
2026-05-07	COGT	34.78	-2.6	-	-2.15
2026-05-08	COGT	34.73	-2.6	-	-2.15
2026-05-11	COGT	34.10	-4.6	-	-2.21
2026-05-12	COGT	34.53	-4.7	-	-2.21
2026-05-13	COGT	34.27	-4.7	-	-2.21
2026-05-14	COGT	34.18	-4.7	-	-2.21
2026-05-15	COGT	32.69	-4.7	-	-2.21
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-17	COGT	-28.59	8.54	12.87
2026-04-20	COGT	-28.59	8.55	12.87
2026-04-21	COGT	-28.59	8.55	12.87
2026-04-22	COGT	-28.59	8.55	12.71
2026-04-23	COGT	-29.94	8.55	12.71
2026-04-24	COGT	-29.94	8.55	12.71
2026-04-27	COGT	-29.94	9.24	8.78
2026-04-28	COGT	-29.94	9.24	8.78
2026-04-29	COGT	-29.94	9.24	8.78
2026-04-30	COGT	-29.94	9.24	8.78
2026-05-01	COGT	-29.94	9.24	8.78
2026-05-04	COGT	-29.94	9.46	8.78
2026-05-05	COGT	-29.94	9.46	8.78
2026-05-06	COGT	-29.94	9.46	8.78
2026-05-07	COGT	-29.94	9.46	8.78
2026-05-08	COGT	-28.88	9.46	8.34
2026-05-11	COGT	-28.90	9.52	8.34
2026-05-12	COGT	-28.90	9.52	8.14
2026-05-13	COGT	-28.90	9.52	8.14
2026-05-14	COGT	-28.90	9.52	8.14
2026-05-15	COGT	-28.90	9.52	8.14
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.53

Avg. EPS Est. Current Quarter

-0.55

Avg. EPS Est. Next Quarter

-0.55

Insider Transactions

-28.9

Institutional Transactions

9.52

Beta

0.34

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

25.3

Max Drawdown 5-Year %

-76.3

Target Price

54.25

P/E

Forward P/E

PEG

P/S

P/B

10.28

P/Free Cash Flow

EPS

-2.52

Average EPS Est. Cur. Y

-2.21

EPS Next Y. (Est.)

-0.94

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.01

Return on Equity vs Sector %

-85.2

Return on Equity vs Industry %

-69.7

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.06

EBIT Estimation

◆ COGT Healthcare

$32.68

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

14/20

Pullback

13/25

Volume

4/15

Valuation

9/20

TP/AR

2/10

Options

6/10

RSI

Range 1M

4.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

11/25

Growth

13/30

Estimates

0/20

Inst/Vol

7/15

Options

4/10

EPS Yr

-3.9%

EPS NY

65.7%

52W%

72%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +66% upside

Quality

2/30

Valuation

12/30

Growth

9/25

Stability

8/10

LT Trend

1/5

Upside

+66%

Quality

Cogent Biosciences, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 258

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

COGT

Latest News

—

Caricamento notizie per COGT…

stock quote shares COGT – Cogent Biosciences Inc Stock Price stock today

news today COGT – Cogent Biosciences Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch COGT – Cogent Biosciences Inc yahoo finance google finance

stock history COGT – Cogent Biosciences Inc invest stock market

stock prices COGT premarket after hours

ticker COGT fair value insiders trading

No more stocks to show

ROIV – Roivant Sciences Ltd

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ROIV

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

RNAM – Avidity Biosciences Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RNAM

No data found

No data found

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y